The Dolutegravir Antiretroviral Mono-Therapy for HIV Trial

Trial Profile

The Dolutegravir Antiretroviral Mono-Therapy for HIV Trial

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Dolutegravir (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms DOMONO
  • Most Recent Events

    • 07 Mar 2018 This study was discontinued prematurely due to an unforeseen number of virological failures with acquired resistance in integrase in 3 patients, according results presented at the 25th Conference on Retroviruses and Opportunistic Infections.
    • 07 Mar 2018 Results (n=85) assessing renal, bone, lipid and inflammatory markers before and after a switch from TDF-containing cART to dolutegravir monotherapy in this study, presented at the 25th Conference on Retroviruses and Opportunistic Infections.
    • 27 Oct 2017 Results presented at the 16th European AIDS Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top